Respiratory
C4XD and AstraZeneca enter $402m deal to develop respiratory disease therapy
C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and…
AbbVie announces acquisition of DJS Antibodies for $255m
AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery…
Health Canada approves Bausch Health-Glenmark’s allergic rhinitis treatment
Health Canada has granted approval for Bausch Health and Glenmark Pharmaceuticals subsidiary Glenmark Specialty’s Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) as a symptomatic therapy…
US FDA approves Vertex’s Orkambi for cystic fibrosis in children
The US Food and Drug Administration (FDA) has approved the expanded usage of Vertex Pharmaceuticals’ Orkambi (lumacaftor/ivacaftor) to treat cystic fibrosis (CF)…
PAN-TB’s Phase II trials take a shot at shorter TB regimens
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is banking on a collaborative approach to scientific innovation to address…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
EC approves Sanofi and Regeneron’s Dupixent for severe asthma in children
The European Commission (EC) has updated the marketing authorization for Sanofi and Regeneron’s Dupixent (adupilumab) to include as an add-on maintenance treatment…
FDA grants breakthrough therapy status to Pfizer’s RSV vaccine
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s respiratory syncytial virus (RSV) vaccine candidate,…
Sanofi obtains CHMP’s positive opinion for severe asthma therapy in children
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided a positive opinion recommending approval…
FDA issues complete response letter for Merck’s chronic cough treatment
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Merck’s (MSD) New Drug Application…
Novavax Covid-19 vaccine to be rolled out in Australia from next month
Australia’s health minister has announced that Novavax’s Covid-19 vaccine will be rolled out across the country from February 21. The…
Covid-19 vaccine mixing: could heterologous boosters improve immunity?
As the world grappled with vaccinating against Covid-19 last year, a mix-and-match approach to jabs emerged as a potential solution…
Moderna eyes combined Covid-19, flu booster by 2023
Moderna is aiming to market a Covid-19 and influenza booster vaccine combo within the next two years, CEO Stéphane Bancel…
Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patients
Cystic fibrosis (CF) is the most common genetic disease among individuals of European descent. The introduction of CF transmembrane conductance…
UK life sciences trade group calls for oral Covid-19 antiviral investment
The UK government needs to further invest in Covid-19 oral antivirals to tackle the SARS-CoV-2 virus and its highly transmissible…
NRx seeks breakthrough therapy designation for Covid-19 treatment
NRx Pharmaceuticals has filed a new breakthrough therapy designation (BTD) request for its therapy Zyesami (aviptadil) in Covid-19 patients. The…